Health Technology · Biotechnology · NSE: HALEOSLABS · data 2026-10-09
Haleos Labs Ltd.
Health check: Average (6.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,563.7
Market cap
₹465 cr
P/E
29.9
P/B
—
ROE
8.4%
ROCE
10.4%
Debt / equity
0.52
Dividend yield
0.10%
1-year return
41.3%
52-week high
₹1,774
52-week low
₹1,091.1
Operating margin
7.7%
Growth
| Revenue (last 12 months) | ₹324 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | 1.9% |
| Profit growth, 3 years (yearly) | 14.7% |
Similar companies
Anthem Biosciences Limited (ANTHEM) · Rubicon Research Limited (RUBICON) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HALEOSLABS in NSE Scanner →